Inhibitor Therapeutics (INTI) Tax Rate (2018 - 2019)
Inhibitor Therapeutics' (INTI) quarterly Tax Rate came in at 1181.66% in Q4 2019, down 66338.0% on a YoY basis from N/an in Q4 2018, and down 127.99% quarter-over-quarter from 518.29% in Q4 2018.
Powered by 
Analysis
Inhibitor Therapeutics (INTI) Tax Rate (2018 - 2019) Analysis & Trends
Inhibitor Therapeutics (INTI) has reported Tax Rate for 2 consecutive years, with 1181.66% the latest figure, recorded in Q4 2019.
- For the quarter ending Q4 2019, Tax Rate fell 66338.0% year-over-year to 1181.66%; the trailing twelve-month figure through Dec 2019 stood at 274.3% (down 12333.0% YoY), and the FY2023 full-year result was 21.0%, up 33.0% from the prior year.
- Tax Rate retreated to 1181.66% in Q4 2019 per INTI's latest filing, from 518.29% in the prior quarter.
- Across five years, Tax Rate topped out at 518.29% in Q4 2018 and bottomed at 1181.66% in Q4 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Tax Rate (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn | 17.98% |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn | 15.47% |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | -95.75% |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn | -23.71% |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 62.33% |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn | -31.96% |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - | - |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn | 22.08% |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn | 10.65% |
| 10 | Inhibitor Therapeutics | 12.17 Mn | 12.17 Mn | - | - |